<DOC>
	<DOCNO>NCT00375895</DOCNO>
	<brief_summary>In France , 50 % hepatitis C virus carrier develop chronic clinical hepatitis , may lead cirrhosis liver transplantation . Transplant infection hepatitis C virus constant transplantation recurrence cause chronic liver disease 50 80 % case . The aim study assess efficacy cyclosporin C virological response . Patients include Transpeg 1 study non-responder recurrent disease switch tacrolimus therapy cyclosporin , association 1 year peginterferon alfa-2a / ribavirin bitherapy . Efficacy assess percentage patient negative qualitative PCR 19 month cyclosporin treatment .</brief_summary>
	<brief_title>Switch From Tacrolimus Cyclosporin Treatment Recurrent Hepatitis C After Liver Transplantation</brief_title>
	<detailed_description>In France , 50 % hepatitis C virus carrier develop chronic clinical hepatitis , may lead cirrhosis liver transplantation . Transplant infection hepatitis C virus constant transplantation . A main factor determine severity recurrent hepatitis C transplantation may immunosuppression . Thus optimization immunosuppressive regimen might key aspect improve prognosis chronic hepatitis C transplant patient . The two frequently use immunosuppressive drug cyclosporin tacrolimus . However , show virus replication could inhibit cyclosporin , blockade cyclophilins , decrease hepatitis C viral load improve liver function . These effect find tacrolimus . The aim study assess efficacy C virological response switch tacrolimus cyclosporin associate peginterferon alfa-2a / ribavirin bitherapy , non-responder recurrent VHC+ disease liver transplant patient . Patients receive 19 month cyclosporin treatment , associate 12 month peginterferon alfa-2a / ribavirin bitherapy . Efficacy assess percentage patient negative qualitative PCR 19 month cyclosporin treatment .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<criteria>Adults age 18 , Who include Transpeg 1 study , Nonresponders three month peginterferon alfa2a / ribavirin bitherapy recurrent disease Transpeg 1 maintenance phase , whatever randomization group ( ribavirin placebo ) , With positive qualitative PCR inclusion , With METAVIR histologic score 1 last biopsy ( do within 6 month precede inclusion ) , Treated tacrolimus least 6 month prior inclusion , Having give write informed consent . Treatment peginterferon ribavirin within 6 month precede inclusion , Severe hepatocellular failure decompensated cirrhosis , Acute graft rejection within two month precede inclusion , sign chronic rejection last biopsy , retransplantation since inclusion Transpeg 1 study , Treatment cyclosporin 6 month 24 month precede inclusion , Treatment mTOR inhibitor another investigational immunosuppressive drug , Positive serology HIV HBV , Cancer ( history malignancy last 5 year ) except patient transplant hepatocellular carcinoma basocellular excise spinocellular carcinoma , Serious concomitant disease acute chronic disorder , current transplant , treated steroid , Serious cardiac pathology within last 6 month , Women ongoing pregnancy breastfeeding , Serious chronic renal failure ( creatinine clearance &lt; 30 ml/mn ) , Haemoglobin &lt; 10 g/dl , platelet &lt; 50 000/mm3 neutrophil &lt; 1000 / mm3 , Abnormal TSH value , Inability cooperate communicate investigator , Contraindications ribavirin , peginterferon alfa2a cyclosporin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Cyclosporin</keyword>
	<keyword>Peginterferon</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>Chronic hepatitis C</keyword>
	<keyword>Liver transplantation</keyword>
</DOC>